Plain-English translation of NCT07099443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is collecting blood and bone marrow samples from people with chronic lymphocytic leukemia (a type of blood cancer) who are being treated with BTK degraders — a newer class of targeted therapy. The researchers want to understand why some patients respond well to this medication while others don't, and to help predict which patients might benefit most from this treatment.
Some patients with blood cancer have become resistant to multiple treatments and have very limited options left. This study aims to identify biological markers that can help doctors predict whether this new treatment will work for a particular patient, and to develop better strategies for those who don't respond well to the medication.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will donate additional blood samples and possibly bone marrow or lymph node tissue at the time you enroll, then again at 6 months, and if your disease returns. These samples will be stored in a research laboratory (called a biobank) and analyzed to understand how your body is responding to the treatment. The study involves no new medications or procedures beyond what you would normally receive as part of your regular cancer care.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
France